{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T18:39:07Z","timestamp":1780598347572,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,9]]},"DOI":"10.7759\/cureus.33563","type":"journal-article","created":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T01:50:35Z","timestamp":1673315435000},"source":"Crossref","is-referenced-by-count":2,"title":["Review of Hematology-Oncology Emergencies for Internal Medicine Residents"],"prefix":"10.7759","author":[{"given":"Bohdan","family":"Baralo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohiel","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhanusowymya C","family":"Buragamadagu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliza","family":"Khanam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahati","family":"Paravathaneni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Mulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verushka","family":"Bedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vihitha","family":"Thota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa","family":"Baralo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhil","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Thirumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"National Cancer Institute. Cancer statistics. (2022). Accessed. January 20, 2022: https:\/\/www.cancer.gov\/ about-cancer\/understanding\/statistics."},{"key":"ref2","article-title":"Oncologic emergencies: recognition and initial management","volume":"97","author":"Higdon ML","year":"2018","unstructured":"Higdon ML, Atkinson CJ, Lawrence KV. Oncologic emergencies: recognition and initial management. Am Fam Physician. 2018, 97:741-8.","journal-title":"Am Fam Physician"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20124","article-title":"Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment","volume":"61","author":"Lewis MA","year":"2011","unstructured":"Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin. 2011, 61:287-314. 10.3322\/caac.20124","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hct244","article-title":"Malignant spinal cord compression: NICE guidance, improvements and challenges","volume":"107","author":"Savage P","year":"2014","unstructured":"Savage P, Sharkey R, Kua T, et al.. Malignant spinal cord compression: NICE guidance, improvements and challenges. QJM. 2014, 107:277-82. 10.1093\/qjmed\/hct244","journal-title":"QJM"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1097\/BRS.0b013e3181e16ae2","article-title":"A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group","volume":"35","author":"Fisher CG","year":"2010","unstructured":"Fisher CG, DiPaola CP, Ryken TC, et al.. A novel classification system for spinal instability in neoplastic disease: an evidence-based approach and expert consensus from the Spine Oncology Study Group. Spine (Phila Pa 1976). 2010, 35:E1221-9. 10.1097\/BRS.0b013e3181e16ae2","journal-title":"Spine (Phila Pa 1976)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.spinee.2015.10.006","article-title":"Spine Instability Neoplastic Score: agreement across different medical and surgical specialties","volume":"16","author":"Arana E","year":"2016","unstructured":"Arana E, Kovacs FM, Royuela A, Asenjo B, P\u00e9rez-Ram\u00edrez \u00da, Zamora J. Spine Instability Neoplastic Score: agreement across different medical and surgical specialties. Spine J. 2016, 16:591-9. 10.1016\/j.spinee.2015.10.006","journal-title":"Spine J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000054661","article-title":"Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries","volume":"44","author":"Annemans L","year":"2003","unstructured":"Annemans L, Moeremans K, Lamotte M, et al.. Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries. Leuk Lymphoma. 2003, 44:77-83. 10.1080\/1042819021000054661","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08143.x","article-title":"Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus","volume":"149","author":"Cairo MS","year":"2010","unstructured":"Cairo MS, Coiffier B, Reiter A, Younes A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol. 2010, 149:578-86. 10.1111\/j.1365-2141.2010.08143.x","journal-title":"Br J Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05094.x","article-title":"Tumour lysis syndrome: new therapeutic strategies and classification","volume":"127","author":"Cairo MS","year":"2004","unstructured":"Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004, 127:3-11. 10.1111\/j.1365-2141.2004.05094.x","journal-title":"Br J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma","volume":"19","author":"Pui CH","year":"2001","unstructured":"Pui CH, Mahmoud HH, Wiley JM, et al.. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma. J Clin Oncol. 2001, 19:697-704. 10.1200\/JCO.2001.19.3.697","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard SC","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011, 364:1844-54. 10.1056\/NEJMra0904569","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S83681","article-title":"Hypercalcemia of malignancy and new treatment options","volume":"11","author":"Sternlicht H","year":"2015","unstructured":"Sternlicht H, Glezerman IG. Hypercalcemia of malignancy and new treatment options. Ther Clin Risk Manag. 2015, 11:1779-88. 10.2147\/TCRM.S83681","journal-title":"Ther Clin Risk Manag"},{"key":"ref13","article-title":"","author":"Yeung SCJ","year":"2003","unstructured":"Yeung SCJ, Pollock RE, Weichselbaum RR, et al.. Holland-Frei Cancer Medicine. 6th edition. BC Decker, Hamilton, ON; 2003. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK12609\/.."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2014-1001","article-title":"Denosumab for treatment of hypercalcemia of malignancy","volume":"99","author":"Hu MI","year":"2014","unstructured":"Hu MI, Glezerman IG, Leboulleux S, et al.. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab. 2014, 99:3144-52. 10.1210\/jc.2014-1001","journal-title":"J Clin Endocrinol Metab"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2010.06.003","article-title":"Evaluation and management of pericardial effusion in patients with neoplastic disease","volume":"53","author":"Maisch B","year":"2010","unstructured":"Maisch B, Ristic A, Pankuweit S. Evaluation and management of pericardial effusion in patients with neoplastic disease. Prog Cardiovasc Dis. 2010, 53:157-63. 10.1016\/j.pcad.2010.06.003","journal-title":"Prog Cardiovasc Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2022.05.001","article-title":"Pericardial tamponade: a comprehensive emergency medicine and echocardiography review","volume":"58","author":"Alerhand S","year":"2022","unstructured":"Alerhand S, Adrian RJ, Long B, Avila J. Pericardial tamponade: a comprehensive emergency medicine and echocardiography review. Am J Emerg Med. 2022, 58:159-74. 10.1016\/j.ajem.2022.05.001","journal-title":"Am J Emerg Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2009.06.009","article-title":"Insulinoma","volume":"89","author":"Mathur A","year":"2009","unstructured":"Mathur A, Gorden P, Libutti SK. Insulinoma. Surg Clin North Am. 2009, 89:1105-21. 10.1016\/j.suc.2009.06.009","journal-title":"Surg Clin North Am"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2004.11.013","article-title":"Imaging and localization of islet-cell tumours of the pancreas on CT and MRI","volume":"19","author":"Noone TC","year":"2005","unstructured":"Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005, 19:195-211. 10.1016\/j.beem.2004.11.013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2404","article-title":"Selective arterial calcium stimulation with hepatic venous sampling differentiates insulinoma from nesidioblastosis","volume":"100","author":"Thompson SM","year":"2015","unstructured":"Thompson SM, Vella A, Thompson GB, Rumilla KM, Service FJ, Grant CS, Andrews JC. Selective arterial calcium stimulation with hepatic venous sampling differentiates insulinoma from nesidioblastosis. J Clin Endocrinol Metab. 2015, 100:4189-97. 10.1210\/jc.2015-2404","journal-title":"J Clin Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.73.864.640","article-title":"Diazoxide treatment for insulinoma: a national UK survey","volume":"73","author":"Gill GV","year":"1997","unstructured":"Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997, 73:640-1. 10.1136\/pgmj.73.864.640","journal-title":"Postgrad Med J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-3382","article-title":"Management of non-islet-cell tumor hypoglycemia: a clinical review","volume":"99","author":"Bodnar TW","year":"2014","unstructured":"Bodnar TW, Acevedo MJ, Pietropaolo M. Management of non-islet-cell tumor hypoglycemia: a clinical review. J Clin Endocrinol Metab. 2014, 99:713-22. 10.1210\/jc.2013-3382","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2610-9","article-title":"The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients","volume":"16","author":"Castillo JJ","year":"2016","unstructured":"Castillo JJ, Glezerman IG, Boklage SH, Chiodo J 3rd, Tidwell BA, Lamerato LE, Schulman KL. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer. 2016, 16:564. 10.1186\/s12885-016-2610-9","journal-title":"BMC Cancer"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.08.029","article-title":"Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes","volume":"59","author":"Doshi SM","year":"2012","unstructured":"Doshi SM, Shah P, Lei X, Lahoti A, Salahudeen AK. Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis. 2012, 59:222-8. 10.1053\/j.ajkd.2011.08.029","journal-title":"Am J Kidney Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.03.004","article-title":"A review of drug-induced hyponatremia","volume":"52","author":"Liamis G","year":"2008","unstructured":"Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008, 52:144-53. 10.1053\/j.ajkd.2008.03.004","journal-title":"Am J Kidney Dis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0400","article-title":"Diagnosis and management of hyponatremia in cancer patients","volume":"17","author":"Castillo JJ","year":"2012","unstructured":"Castillo JJ, Vincent M, Justice E. Diagnosis and management of hyponatremia in cancer patients. Oncologist. 2012, 17:756-65. 10.1634\/theoncologist.2011-0400","journal-title":"Oncologist"},{"key":"ref26","article-title":"Oncological emergencies associated with gastrointestinal tumors","volume":"28","author":"Prenen K","year":"2015","unstructured":"Prenen K, Prenen H. Oncological emergencies associated with gastrointestinal tumors. Ann Gastroenterol. 2015, 28:426-30.","journal-title":"Ann Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2018.10.024","article-title":"Emergency medicine evaluation and management of small bowel obstruction: evidence-based recommendations","volume":"56","author":"Long B","year":"2019","unstructured":"Long B, Robertson J, Koyfman A. Emergency medicine evaluation and management of small bowel obstruction: evidence-based recommendations. J Emerg Med. 2019, 56:166-76. 10.1016\/j.jemermed.2018.10.024","journal-title":"J Emerg Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.022210","article-title":"Management of malignant bowel obstruction associated with GI cancers","volume":"13","author":"Franke AJ","year":"2017","unstructured":"Franke AJ, Iqbal A, Starr JS, Nair RM, George TJ Jr. Management of malignant bowel obstruction associated with GI cancers. J Oncol Pract. 2017, 13:426-34. 10.1200\/JOP.2017.022210","journal-title":"J Oncol Pract"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.5712","article-title":"Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Mariani P","year":"2012","unstructured":"Mariani P, Blumberg J, Landau A, et al.. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2012, 30:4337-43. 10.1200\/JCO.2011.40.5712","journal-title":"J Clin Oncol"},{"key":"ref30","article-title":"Cancer: Principles and Practice of Oncology","author":"Loeffler JS","year":"1997","unstructured":"Loeffler JS, Sawaya R., H, S. DeVita VT Jr, Rosenberg SA. Cancer: Principles and Practice of Oncology. Lippincott-Raven Publishers, Philadelphia, PA; 1997."},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.9589","article-title":"Whole-brain radiotherapy for brain metastases: evolution or revolution?","volume":"36","author":"Brown PD","year":"2018","unstructured":"Brown PD, Ahluwalia MS, Khan OH, Asher AL, Wefel JS, Gondi V. Whole-brain radiotherapy for brain metastases: evolution or revolution?. J Clin Oncol. 2018, 36:483-91. 10.1200\/JCO.2017.75.9589","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1177\/0885066615619582","article-title":"Neurologic emergencies in the patients with cancer","volume":"32","author":"Lin AL","year":"2017","unstructured":"Lin AL, Avila EK. Neurologic emergencies in the patients with cancer. J Intensive Care Med. 2017, 32:99-115. 10.1177\/0885066615619582","journal-title":"J Intensive Care Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.71.8.633","article-title":"Acute leukemia with a very high leukocyte count: confronting a medical emergency","volume":"71","author":"Majhail NS","year":"2004","unstructured":"Majhail NS, Lichtin AE. Acute leukemia with a very high leukocyte count: confronting a medical emergency. Cleve Clin J Med. 2004, 71:633-7. 10.3949\/ccjm.71.8.633","journal-title":"Cleve Clin J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3109\/10428190009053534","article-title":"Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management","volume":"39","author":"Porcu P","year":"2000","unstructured":"Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, McCarthy LJ. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000, 39:1-18. 10.3109\/10428190009053534","journal-title":"Leuk Lymphoma"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-846816","article-title":"Acute hyperviscosity: syndromes and management","volume":"132","author":"Gertz MA","year":"2018","unstructured":"Gertz MA. Acute hyperviscosity: syndromes and management. Blood. 2018, 132:1379-85. 10.1182\/blood-2018-06-846816","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos MA","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, et al.. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018, 378:2399-410. 10.1056\/NEJMoa1802917","journal-title":"N Engl J Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03080190030008","article-title":"Serum hyperviscosity syndrome","volume":"192","author":"Fahey JL","year":"1965","unstructured":"Fahey JL, Barth BF, Solomon A. Serum hyperviscosity syndrome. JAMA. 1965, 192:464-7. 10.1001\/jama.1965.03080190030008","journal-title":"JAMA"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-141728","article-title":"Epidemiology and outcomes of hospitalizations due to Waldenstrom macroglobulinemia: a national perspective","volume":"136","author":"Siddarath B","year":"2020","unstructured":"Siddarath B, Agrawal D, Deshpande S, et al.. Epidemiology and outcomes of hospitalizations due to Waldenstrom macroglobulinemia: a national perspective. Blood. 2020, 136:37. 10.1182\/blood-2020-141728","journal-title":"Blood"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue","volume":"34","author":"Padmanabhan A","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N, et al.. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019, 34:171-354. 10.1002\/jca.21705","journal-title":"J Clin Apher"},{"key":"ref40","article-title":"Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study","volume":"43","author":"Ballestri M","year":"2007","unstructured":"Ballestri M, Ferrari F, Magistroni R, et al.. Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study. Ann Ist Super Sanita. 2007, 43:171-5.","journal-title":"Ann Ist Super Sanita"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6211","article-title":"Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update","volume":"36","author":"Taplitz RA","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, et al.. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America clinical practice guideline update. J Clin Oncol. 2018, 36:1443-53. 10.1200\/JCO.2017.77.6211","journal-title":"J Clin Oncol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-14-162","article-title":"Time to antibiotics and outcomes in cancer patients with febrile neutropenia","volume":"14","author":"Perron T","year":"2014","unstructured":"Perron T, Emara M, Ahmed S. Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Serv Res. 2014, 14:162. 10.1186\/1472-6963-14-162","journal-title":"BMC Health Serv Res"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.09.016","article-title":"CISNE versus MASCC: identifying low risk febrile neutropenic patients","volume":"38","author":"Mohindra R","year":"2020","unstructured":"Mohindra R, Mathew R, Yadav S, Aggarwal P. CISNE versus MASCC: identifying low risk febrile neutropenic patients. Am J Emerg Med. 2020, 38:2259-63. 10.1016\/j.ajem.2019.09.016","journal-title":"Am J Emerg Med"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.018","article-title":"Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations","volume":"134","author":"Jerschow E","year":"2014","unstructured":"Jerschow E, Lin RY, Scaperotti MM, McGinn AP. Fatal anaphylaxis in the United States, 1999-2010: temporal patterns and demographic associations. J Allergy Clin Immunol. 2014, 134:1318-28.e7. 10.1016\/j.jaci.2014.08.018","journal-title":"J Allergy Clin Immunol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.015","article-title":"Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases","volume":"123","author":"Hong D","year":"2019","unstructured":"Hong D, Sloane DE. Hypersensitivity to monoclonal antibodies used for cancer and inflammatory or connective tissue diseases. Ann Allergy Asthma Immunol. 2019, 123:35-41. 10.1016\/j.anai.2019.04.015","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2016.09.055","article-title":"Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review","volume":"2","author":"Jhaveri KD","year":"2017","unstructured":"Jhaveri KD, Wanchoo R, Sakhiya V, Ross DW, Fishbane S. Adverse renal effects of novel molecular oncologic targeted therapies: a narrative review. Kidney Int Rep. 2017, 2:108-23. 10.1016\/j.ekir.2016.09.055","journal-title":"Kidney Int Rep"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8556-5","article-title":"Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies","volume":"54","author":"Bonamichi-Santos R","year":"2018","unstructured":"Bonamichi-Santos R, Castells M. Diagnoses and management of drug hypersensitivity and anaphylaxis in cancer and chronic inflammatory diseases: reactions to taxanes and monoclonal antibodies. Clin Rev Allergy Immunol. 2018, 54:375-85. 10.1007\/s12016-016-8556-5","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.10.039","article-title":"Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions","volume":"137","author":"Picard M","year":"2016","unstructured":"Picard M, Pur L, Caiado J, et al.. Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016, 137:1154-64.e12. 10.1016\/j.jaci.2015.10.039","journal-title":"J Allergy Clin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/95417-review-of-hematology-oncology-emergencies-for-internal-medicine-residents","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:54:22Z","timestamp":1707508462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/95417-review-of-hematology-oncology-emergencies-for-internal-medicine-residents"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":48,"URL":"https:\/\/doi.org\/10.7759\/cureus.33563","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,9]]}}}